Pfizer’s megablockbuster-to-be COVID pill Paxlovid scores FDA nodnews2021-12-22T18:12:50+00:00December 22nd, 2021|Fierce Pharma|
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulatorsnews2021-12-22T14:18:18+00:00December 22nd, 2021|Fierce Pharma|
Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavirnews2021-12-22T14:15:55+00:00December 22nd, 2021|Fierce Pharma|
With Sanofi’s mighty Dupixent chasing behind, Takeda’s Eohilia suffers FDA rejection after mysterious delaynews2021-12-22T12:41:38+00:00December 22nd, 2021|Fierce Pharma|
When medicine is the hero, you need a Sidekick to stay the coursenews2021-12-22T11:32:31+00:00December 22nd, 2021|Fierce Pharma|
Girding for BMS competition, Amgen wins another plaque psoriasis nod for Otezlanews2021-12-21T16:24:32+00:00December 21st, 2021|Fierce Pharma|
AbbVie, after losing Humira trade secrets case, eyes new strategy in Alvotech fightnews2021-12-21T16:00:07+00:00December 21st, 2021|Fierce Pharma|
GlaxoSmithKline’s HIV prevention injectable Apretude threatens Gilead with FDA blessing. But will doctors use it?news2021-12-21T15:34:06+00:00December 21st, 2021|Fierce Pharma|
Amgen to spend $100M to build new vial filling line at Dublin site: reportnews2021-12-21T14:47:05+00:00December 21st, 2021|Fierce Pharma|
Turkish biotech bags $12M for targeted delivery of cancer drugsnews2021-12-21T14:28:34+00:00December 21st, 2021|Fierce Pharma|
